Bill Desmarais is Alchemab’s Chief Business Officer where he focuses on executing the company’s global business development and strategic transactions. Prior to joining Alchemab, Bill was Chief Business Officer at TScan Therapeutics, where he led a key discovery platform transaction with Amgen. Prior to joining TScan, Bill held senior business development roles at Momenta Pharmaceuticals and Global External R&D at Eli Lilly. Over his career, Bill has executed transactions with a total value of over $7 billion.

Bill holds an MBA from Massachusetts Institute of Technology, a PhD in Biophysics from Brandeis University and a BS in Biology from Purdue University. In his free time, he runs a local youth organization whose mission is to develop leaders of character.